Comparison

AT9283 European Partner

Item no. S1134-1000
Manufacturer Selleckchem
CASRN 896466-04-9
Amount 1 g
Quantity options 10 mg 100 mg 1 g 10 g 10 mM/1 mL 2 mg 5 mg 50 mg 5 g
Category
Type Inhibitors
Specific against other
Smiles C1CC1NC(=O)NC2=C(NN=C2)C3=NC4=C(N3)C=C(C=C4)CN5CCOCC5
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias 896466-04-9'
Similar products AT9283
Available
Manufacturer - Targets
JAK3, JAK2
Storage Conditions
2 years -80 in solvent
Molecular Weight
381, 43
Administration
Administered via i.p.
Animal Models
HCT116 cells are injected s.c. Into the hind flank of male BALB/c mice.
Cell lines
HCT 116 cells
Clinical Trials
AT9283 is currently in Phase I clinical trials in patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma.
Concentrations
1 nM - 10 uM
Dosages
15 mg/kg and 20 mg/kg
Formulation
Belinostat is dissolved in 10% DMSO, 20% water, 70% hydroxypropyl- beta-cyclodextrin (25% w/v aq).
IC50
3 nM, 3 nM, 3 nM, 3 nM, 3 nM, 3 nM
In vitro
AT9283 leads to a clear polyploid phenotype by inhibiting the activity of Aurora B kinase in HCT116 cells with IC50 of 30 nM. Furthermore, AT9283 also produces the potent inhibition on HCT116 colony formation. [1]
In vivo
In HCT116 human colon carcinoma xenograft bearing mice, AT9283 treatment (15 mg/kg and 20 mg/kg) for 16 days results in a significant tumor growth inhibition of 67% and 76%, respectively. In addition, AT9283 also exhibits a significantly longer half-life in tumors(2.5 hours) compared with plasma (0.5 hour) and modest oral bioavailability in mice (Fp.o. = 24%). [1]
Incubation Time
72 hours
Kinase Assay
Aurora A and Aurora B Kinase Assays, Assays for Aurora A and B are performed in a DELFIA format. Aurora A enzyme is incubated with AT9283 and 3 uM cross-tide substrate (biotin-CGPKGPGRRGRRRTSSFAEG) in 10 mM MOPS, pH 7, 0.1 mg/mL BSA, 0.001% Brij-35, 0.5% glycerol, 0.2 mM EDTA, 10 mM MgCl2, 0.01% beta-mercaptoethanol, 15 uM ATP, and 2.5% DMSO. Aurora B enzyme is incubated with AT9283, 3 uM of the above substrate in 25 mM Tris, pH 8.5, 5 mM MgCl2, 0.1 mg/mL BSA, 0.025% Tween-20, 1 mM DTT, 15 uM ATP, and 2.5% DMSO. Reactions are allowed to proceed for 60 minutes and 45-90 minutes for Aurora A and Aurora B, respectively, before quenching with EDTA. The reaction mixtures are then transferred to a neutravidin-coated plate, and phosphorylated peptide is quantified by means of a phospho-specific antibody and a europium labeled secondary antibody using time-resolved fluorescence (excitation, 337 nm, emission, 620 nm). IC50 values for the control compounds are 92 nM (Aurora A assay) and 17 nM (Aurora B).
Method
HCT 116 cells are cultured in DMEM + 10% FBS + GLUTAMAX I. Black 96-well flat-bottomed (clear) tissue culture treated plates are seeded in 200 L of medium and incubated for approximately 16 hours at 37C in a humidified atmosphere of 5% CO2 in air. Cells are treated with test compound at nine different concentrations (spanning 1 nM to 10 M, plus DMSO vehicle control) and then incubated for 72 hours. Polyploidy morphological observations of the cells are then noted. The concentration of AT9283 required to produce a distinct polyploid phenotype is reported. Cells are seeded at a concentration of 75100 cells/mL relevant culture media onto 6- or 24-well tissue culture plates and allowed to recover for 16 hours. Test compound (11 concentrations spanning 0.1 nM to 10 M) or vehicle control (DMSO) is added to duplicate wells to give a final DMSO concentration of 0.1%. Following compound addition, colonies are allowed to grow between 10 and 14 days for optimum discrete colony counting. Colonies are fixed in 2 mL of Carnoys fixative (25% acetic acid, 75% MeOH) and stained in 2 mL of 0.4% w/v crystal violet. The numbers of colonies in each well is counted. IC50 values are calculated by sigmoidal dose-response (variable slope) IC50 curves using Prism Graphpad software.
Solubility (25C)
DMSO 76 mg/mL, Water <1 mg/mL, Ethanol 38 mg/mL
Information
AT9283 is a potent JAK2/3 inhibitor with IC50 of 1.2 nM/1.1 nM in cell-free assays; also potent to Aurora A/B, Abl1(T315I).
Chemical Name
1-cyclopropyl-3-(3-(5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)urea

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 1 g
Available: In stock
available

Delivery expected until 7/17/2025 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?